Neuropilin-2 expression in cancer

Histopathology

Volumn 61, Issue 3, 2012, Pages 340-349

  Jubb, Adrian M ^a   Sa, Susan M ^a   Ratti, Navneet ^a   Strickland, Laura A ^a   Schmidt, Maike ^a   Callahan, Christopher A ^a   Koeppen, Hartmut ^a  

^a GENENTECH INC   (United States)

Author keywords

Cancer; Immunohistochemistry; In situ hybridization; Neuropilin 2

Indexed keywords

MESSENGER RNA; NEUROPILIN 2;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; BREAST METASTASIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER TISSUE; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MELANOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; TISSUE SECTION; TUMOR CELL; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; HUMANS; IN SITU HYBRIDIZATION; MICE; NEOPLASMS; NEUROPILIN-2; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865375139     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04224.x     Document Type: Article

References (25)

1. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006; 12; 5018-5022.
2. Jeltsch M, Kaipainen A, Joukov V et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997; 276; 1423-1425.
3. Gille H, Kowalski J, Li B et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 2001; 276; 3222-3230.
4. Laakkonen P, Waltari M, Holopainen T et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007; 67; 593-599.
5. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007; 109; 1010-1017.
6. Valtola R, Salven P, Heikkila P et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 1999; 154; 1381-1390.
7. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362; 841-844.
8. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 1995; 95; 1789-1797.
9. Skobe M, Hawighorst T, Jackson DG et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001; 7; 192-198.
10. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 2002; 85; 357-368.
11. Favier B, Alam A, Barron P et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006; 108; 1243-1250.
12. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med. 2002; 12; 13-19.
13. Pan Q, Chathery Y, Wu Y et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J. Biol. Chem. 2007; 282; 24049-24056.
14. Yuan L, Moyon D, Pardanaud L et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002; 129; 4797-4806.
15. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J. Pathol. 2007; 212; 237-248.
16. Xu Y, Yuan L, Mak J et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J. Cell Biol. 2010; 188; 115-130.
17. Caunt M, Mak J, Liang WC et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008; 13; 331-342.
18. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M. Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin. Cancer Res. 2004; 10; 581-590.
19. Gray MJ, Van Buren G, Dallas NA et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl Cancer Inst. 2008; 100; 109-120.
20. Lantuejoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J. Pathol. 2003; 200; 336-347.
21. Cohen T, Herzog Y, Brodzky A et al. Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. J. Pathol. 2002; 198; 77-82.
22. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput insitu studies. J. Pathol. 2001; 195; 72-79.
23. Jubb AM, Pham TQ, Frantz GD, Peale FV Jr, Hillan KJ. Quantitative in situ hybridization of tissue microarrays. Methods Mol. Biol. 2006; 326; 255-264.
24. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 expression in cancer and development. J. Pathol. 2012; 226; 50-56.
25. Stine MJ, Wang CJ, Moriarty WF et al. Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res. 2011; 71; 2433-2444.